Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

NCT02492737 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome
Hematologic Malignancies

Interventions

DRUG: AG881

Sponsor

Agios Pharmaceuticals, Inc.